About PaxVax
PaxVax is a company based in San Diego (United States) founded in 2007 was acquired by Emergent BioSolutions in August 2018. PaxVax has raised $211.78 million across 9 funding rounds from investors including Emergent BioSolutions, Ignition Capital and Cerberus Capital Management. The company has 138 employees as of December 31, 2018. PaxVax operates in a competitive market with competitors including Vir Biotechnology, Vaxcyte, Cidara Therapeutics, HOOKIPA Pharma and Freeline, among others.
- Headquarter San Diego, United States
- Employees 138 as on 31 Dec, 2018
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Paxvax, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$211.78 M (USD)
in 9 rounds
-
Latest Funding Round
$105 M (USD), Series C
Dec 08, 2015
-
Investors
Emergent BioSolutions
& 5 more
-
Employee Count
138
as on Dec 31, 2018
-
Acquired by
Emergent BioSolutions
(Aug 09, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of PaxVax
PaxVax has successfully raised a total of $211.78M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $105 million completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PaxVax
PaxVax has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Emergent BioSolutions, Ignition Capital and Cerberus Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Private equity and debt firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Impact investments are managed through a diversified family office portfolio.
|
Locked | Locked | Locked |
Investor details for PaxVax
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PaxVax
Investment portfolio details for PaxVax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PaxVax
Detailed financials for PaxVax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Paxvax Comparisons
Peer comparison for PaxVax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PaxVax
PaxVax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vir Biotechnology, Vaxcyte, Cidara Therapeutics, HOOKIPA Pharma and Freeline, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| Locked | Locked | Locked |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Gene therapy platform is developed for chronic disease treatments.
|
|
| Locked | Locked | Locked |
Allergen immunotherapies for respiratory allergies are developed.
|
Detailed competitors of PaxVax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Paxvax
Complete news archive for PaxVax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PaxVax
PaxVax was founded in 2007 and raised its 1st funding round 2 years after it was founded.
PaxVax is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
PaxVax is a funded company, having raised a total of $211.78M across 9 funding rounds to date.
As of Dec 31, 2018, the latest employee count at PaxVax is 138.
PaxVax was founded in 2007 in San Diego, United States, within the biotechnology sector focused on infectious disease prevention. Vaccine candidates are developed and commercialized, including PXVX0200 as a single-dose oral cholera vaccine, PXVX0103 for avian influenza, and an anthrax protection candidate. Ad4-env Clade C is advanced as an HIV vaccine component, while Vivotif is commercialized for typhoid fever. Operations emphasize oral administration technologies.
PaxVax's top competitors include Vaxcyte, HOOKIPA Pharma and Serum Institute of India.
PaxVax has 6 investors. Key investors include Emergent BioSolutions, Ignition Capital, Cerberus Capital Management, BioPharma Funds, and Blue Haven Initiative.